News headlines about Cidara Therapeutics (NASDAQ:CDTX) have trended positive recently, according to Alpha One Sentiment Analysis. The research group, a service of Accern, identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cidara Therapeutics earned a media sentiment score of 0.31 on Alpha One’s scale. Alpha One also gave news headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have impacted AlphaOne Sentiment Analysis’s rankings:
- Cidara Therapeutics, Inc. (CDTX) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel (finance.yahoo.com)
- Cidara To Participate In The 2017 BIO International Convention (biospace.com)
- Cidara Therapeutics to Participate in the 2017 BIO International Convention (finance.yahoo.com)
- Short Interest in Cidara Therapeutics, Inc. (CDTX) Rises By 42.7% (americanbankingnews.com)
Several analysts recently commented on the stock. Wedbush restated an “outperform” rating and set a $22.00 price target (up previously from $13.00) on shares of Cidara Therapeutics in a research report on Tuesday, February 21st. Needham & Company LLC dropped their target price on shares of Cidara Therapeutics from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, February 21st. WBB Securities raised shares of Cidara Therapeutics from a “sell” rating to a “hold” rating and set a $7.25 price target on the stock in a research note on Wednesday, February 22nd. HC Wainwright reissued a “buy” rating and issued a $18.00 price target (down from $25.00) on shares of Cidara Therapeutics in a research note on Wednesday, February 22nd. Finally, Zacks Investment Research raised shares of Cidara Therapeutics from a “sell” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Thursday, February 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.75.
Shares of Cidara Therapeutics (NASDAQ:CDTX) traded down 0.73% during midday trading on Monday, reaching $6.80. 137,109 shares of the company were exchanged. The company’s market capitalization is $114.28 million. Cidara Therapeutics has a 52-week low of $5.65 and a 52-week high of $12.95. The firm’s 50 day moving average is $6.78 and its 200-day moving average is $8.35.
Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. On average, equities analysts forecast that Cidara Therapeutics will post ($3.43) earnings per share for the current fiscal year.
In related news, insider Kevin Forrest bought 12,500 shares of Cidara Therapeutics stock in a transaction that occurred on Friday, March 31st. The stock was purchased at an average cost of $7.75 per share, for a total transaction of $96,875.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey Stein bought 12,900 shares of Cidara Therapeutics stock in a transaction that occurred on Friday, March 31st. The stock was bought at an average price of $7.75 per share, with a total value of $99,975.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 60,400 shares of company stock valued at $404,100. 22.20% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Cidara Therapeutics (CDTX) Receiving Positive Press Coverage, Analysis Shows” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/cidara-therapeutics-cdtx-earns-media-impact-score-of-0-31-updated-updated-updated/804297.html.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with our FREE daily email newsletter.